Navigation Links
Children's Hospital scientists achieve repair of injured heart muscle in lab tests of stem cells
Date:11/25/2008

Researchers at Children's Hospital of Pittsburgh of UPMC have been able to effectively repair damaged heart muscle in an animal model using a novel population of stem cells they discovered that is derived from human skeletal muscle tissue.

The research team led by Johnny Huard, PhD transplanted stem cells purified from human muscle-derived blood vessels into the hearts of mice that had heart damage similar to that which would occur in people who had suffered a heart attack.

These transplanted myoendothelial cells repaired the injured muscle, stimulated the growth of new blood vessels in the heart and reduced scar tissue from the injury, thereby dramatically improving the function of the injured left ventricle, said Dr. Huard, director of the Stem Cell Research Center at Children's Hospital's John G. Rangos Sr. Research Center.

"This study confirms our belief that this novel population of stem cells discovered in our laboratory holds tremendous promise for the future of regenerative medicine. Specifically, myoendothelial cells show potential as a therapy for people who have suffered a myocardial infarction," said Dr. Huard, also the Henry J. Mankin Professor and vice chair for research in the Department of Orthopaedic Surgery, University of Pittsburgh School of Medicine. "The important benefit of our approach is that as a therapy, it would be an autologous transplant. This means that for a patient who suffers a heart attack, we would take a muscle biopsy from his or her muscle, isolate and purify the myoendothelial cells, and re-inject them into the injured heart muscle, thereby avoiding any risk of rejection by introducing foreign cells."

Results of this study are published in the Dec. 2 issue of the Journal of the American College of Cardiology.

The myoendothelial cells used in this study were more effective at repairing the injured cardiac muscle and reducing scar tissue than previous approaches that have used muscle cells known as myoblasts, according to Dr. Huard. At six weeks after injection, the myoendothelial cell-injected hearts functioned at 40 to 50 percent more effectively compared with hearts that had been injected with myogenic cells (myoblasts).


'/>"/>

Contact: Marc Lukasiak
marc.lukasiak@chp.edu
412-692-7919
Children's Hospital of Pittsburgh
Source:Eurekalert

Related biology news :

1. Rhode Island Hospital simulation center examines benefits and applications of medical simulation
2. First results from hospital trials testing
3. Field-hospital-on-a-chip project awarded to nanoengineer from UC San Diego
4. Brown University and Women & Infants Hospital expand national childrens study to Bristol County
5. Childrens Hospital researchers identify genetic mutation that may predict organ rejection
6. Rhode Island Hospital study finds link between obesity, type 2 diabetes and neurodegeneration
7. Childrens Memorial Hospital of Chicago receives a grant from BioMarin to support adult PKU outreach
8. Montreal Heart Institute and Mount Sinai Hospital researchers contribute to Crohns disease study
9. Childrens Hospital leads projects to develop nations first heart assist devices for young children
10. Clinical trial that may help patients breathe easier begins at Central DuPage Hospital
11. MRSA in hospital intensive care -- whats growing where?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2016)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is pleased to announce that the company has been ... Awards as "Most Outstanding in eClinical Solutions" for ... recognition and growth for MedNet, which has effectively supported ... iMedNet ™ , MedNet,s flagship eClinical technology ...
(Date:11/17/2016)... Global Market Watch: Primarily supported by ownership types; ... Academics) market is to witness a value of US$37.1 billion ... Compounded Annual Growth Rate (CAGR) of 10.75% is foreseen from ... 2014-2020. North America is not way ... Europe at 9.56% respectively. Report Focus: ...
(Date:11/15/2016)... 2016  Synthetic Biologics, Inc. (NYSE MKT: SYN), ... the gut microbiome, today announced the pricing of ... its common stock and warrants to purchase 50,000,000 ... to the public of $1.00 per share and ... the offering, excluding the proceeds, if any from ...
Breaking Biology News(10 mins):
(Date:12/2/2016)... ... December 01, 2016 , ... ... value of DNA microarray comparative genomic hybridization (array CGH) for HER2 genomic ... Symposium. Using molecular test results from tumors with previously documented positive, negative, ...
(Date:12/2/2016)... ... December 01, 2016 , ... PhUSE will build ... popularity of US Single Day Events (SDE) to organize a multiple-day US conference. ... Raleigh, NC. Topics of the pharmaceutical and life sciences industry will cover industry ...
(Date:12/2/2016)... ... December 01, 2016 , ... DrugDev believes the only ... a beautiful technology experience. All three tenets were on display at the 2nd Annual ... from over 40 sponsor, CRO and site organizations to discuss innovation and the future ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... consortium of pharmaceutical and biotechnology companies dedicated to collaboratively developing improved chemistry, ... in supplying a vendor-supported, portable online UHPLC, with robust, probe-based sampling. ...
Breaking Biology Technology: